Why is it necessary to allow enough time for medicines agencies to evaluate new medicines? Leaflet 1

Why is it necessary to regularly re-evaluate the benefits and risks of medicines? Leaflet 2

Why should access to independent information on the risks of medicines be guaranteed? Leaflet 3

Why use the INN (International Nonprorietary Name) rather than the brand name of a medicine? Leaflet 4

Why can the centralised procedure for
marketing authorisations be extended without negative consequence for national medicines agencies? Leaflet 5

Why can't pharmaceutical firms convey any other information than promotional stuff? Leaflet 6

Why is real therapeutic innovation so rare? Leaflet 7

Why must there be a European regulatory framework to guarantee "compassionate use" of medicines in terminally ill patients? Leaflet 8

Why should the length of data protection for medicines not be extended? Leaflet 9

Why is it important to have access to documents of the European Medicines Evaluation Agency (EMEA)? Leaflet 10

Why is it necessary to switch the European Medicines Evaluation Agency (EMEA) to the Directorate General of the European Commission responsible for health and consumer protection? Leaflet 11